Novel anti-cholinergics in COPD

Drug Discovery Today

Volumn 18, Issue 21-22, 2013, Pages 1117-1126

  Prakash, A ^a   Babu, K S ^b   Morjaria, J B ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; ALKS 27; AZD 9164; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHF 5407; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CICLESONIDE; DAROTROPIUM BROMIDE; FLUTICASONE; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; INDACATEROL; IPRATROPIUM BROMIDE; LONG ACTING DRUG; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL; OXITROPIUM BROMIDE; PF 4522791; PLACEBO; RBX 343E 48F 0; SALMETEROL; TD 4208; TIOTROPIUM BROMIDE; TROSPIUM CHLORIDE; UMECLIDINIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VILANTEROL;

ABSENCE OF SIDE EFFECTS; BRONCHODILATATION; CELL TYPE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY DEVICE; HUMAN; INHALER; NONHUMAN; POWDER INHALER; REVIEW; UNSPECIFIED SIDE EFFECT;

ACETYLCHOLINE; ANIMALS; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG INDUSTRY; HUMANS; PATENTS AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, MUSCARINIC; SIGNAL TRANSDUCTION;

EID: 84886952590     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.07.005     Document Type: Review

References (73)

1. K.F. Rabe Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Am. J. Respir. Crit. Care Med. 176 6 2007 532 555
2. Global Initiative for Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease 2011
3. M.G. Matera Novel bronchodilators for the treatment of chronic obstructive pulmonary disease Trends Pharmacol. Sci. 32 8 2011 495 506
4. P.J. Barnes The role of anticholinergics in chronic obstructive pulmonary disease Am. J. Med. 117 Suppl 12A 2004 24S 32S
5. K.E. Belmonte Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease Proc. Am. Thorac. Soc. 2 4 2005 297 304 discussion 311-292
6. N.J. Gross, and M.S. Skorodin Role of the parasympathetic system in airway obstruction due to emphysema N. Engl. J. Med. 311 7 1984 421 425
7. E. Flohr, and K.O. Bischoff Oxitropium bromide, a new anticholinergic drug, in a dose-response and placebo comparison in obstructive airway diseases Respiration 38 2 1979 98 104
8. B. Disse Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease Life Sci. 64 6-7 1999 457 464
9. D.P. Tashkin A 4-year trial of tiotropium in chronic obstructive pulmonary disease N. Engl. J. Med. 359 15 2008 1543 1554
10. P.M. Calverley COPD: what is the unmet need? Br. J. Pharmacol. 155 4 2008 487 493
11. M.R. Partridge Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey Curr. Med. Res. Opin. 25 8 2009 2043 2048
12. A. Agusti Night-time symptoms: a forgotten dimension of COPD Eur. Respir. Rev. 20 121 2011 183 194
13. M.P. Caulfield, and N.J. Birdsall International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors Pharmacol. Rev. 50 2 1998 279 290
14. C.J. van Koppen Autoradiographic visualization of muscarinic receptors in pulmonary nerves and ganglia Neurosci. Lett. 83 3 1987 237 240
15. R. Gosens Muscarinic receptor signaling in the pathophysiology of asthma and COPD Respir. Res. 7 2006 73
16. R.M. Eglen Muscarinic receptor subtypes and smooth muscle function Pharmacol. Rev. 48 4 1996 531 565
17. G. Villetti Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5- trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1- azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 receptor antagonist J. Pharmacol. Exp. Ther. 335 3 2010 622 635
18. E.J. Paredes-Gamero Heparin induces rat aorta relaxation via integrin-dependent activation of muscarinic M3 receptors Hypertension 56 4 2010 713 721
19. G. Karakiulakis, and M. Roth Muscarinic receptors and their antagonists in COPD: anti-inflammatory and antiremodeling effects Mediators Inflamm. 2012 2012 409580
20. R.D. Restrepo Use of inhaled anticholinergic agents in obstructive airway disease Respir. Care 52 7 2007 833 851
21. E.B. Haddad Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways Br. J. Pharmacol. 127 2 1999 413 420
22. D.A. Sykes The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium J. Pharmacol. Exp. Ther. 343 2 2012 520 528
23. R. Thomas Low systemic exposure of NVA237, an inhaled once-daily antimuscarinic bronchodilator, in healthy human volunteers Proc. Am. Thorac. Soc. 3 2006 A725
24. C. Verkindre Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients Respir. Med. 104 10 2010 1482 1489
25. C. Vogelmeier Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients Pulm. Pharmacol. Ther. 23 5 2010 438 444
26. C. Fogarty Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients Respir. Med. 105 3 2011 337 342
27. H. Arievich A novel model-based approach for dose determination of glycopyrronium bromide in COPD BMC Pulm. Med. 12 2012 74
28. D. Singh, P.A. Corris, and S.D. Snape NVA237, a once-daily inhaled antimuscarinic, provides 24-hour bronchodilator efficacy with comparable bronchodilation to albuterol in patients with moderate-to-severe COPD Proc. Am. Thorac. Soc. 3 2006 A113
29. A. D'Urzo Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial Respir. Res. 12 2011 156
30. E. Kerwin Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Eur. Respir. J. 40 5 2012 1106 1114
31. K.M. Beeh Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial Int. J. Chron. Obstruct. Pulmon. Dis. 7 2012 503 513
32. S.I. Rennard A novel glycopyrrolate metered dose inhaler formulation demonstrates superior bronchodilator efficacy relative to placebo and comparable efficacy and safety to Spiriva Handihalerin patients with COPD Am. J. Respir. Crit. Care Med. 181 2010 A4450
33. C. Orevillo Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomised, double-blind, placebo-controlledphase 2b study in patients with COPD Eur. Respir. J. 38 Suppl 55, 724s 2011 A3975
34. D. Singh Efficacy and safety of nebulized glycopyrrolate (EP-101) for administration using high efficiency nebulizer in patients with COPD Eur. Respir. J. 38 Suppl 55, 147s 2011 A865
35. C. Fogarty The GOLDEN-1 study: safety and bronchodilatory effects of nebulized glycopyrrolate (EP-101) using high efficiency nebulizer in patients with COPD Eur. Respir. J. 40 Suppl 56, 393s 2012 A2194
36. P. Casarosa Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs J. Pharmacol. Exp. Ther. 330 2 2009 660 668
37. A. Gavalda Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile J. Pharmacol. Exp. Ther. 331 2 2009 740 751
38. M. Cazzola Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur. Respir. J. 31 2 2008 416 469
39. J.E. Frampton Aclidinium: in chronic obstructive pulmonary disease Drugs 72 15 2012 1999 2011
40. H. Magnussen Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD Respir. Med. 103 12 2009 1832 1837
41. P. Brand Lung deposition of radiolabeled tiotropium in healthy subjects and patients with chronic obstructive pulmonary disease J. Clin. Pharmacol. 47 10 2007 1335 1341
42. K. Schmid Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: a phase I, open-label, single-dose clinical trial Clin. Ther. 32 10 2010 1798 1812
43. R. Fuhr Efficacy of aclidinium bromide 400 mug twice daily compared with placebo and tiotropium in patients with moderate to severe COPD Chest 141 3 2012 745 752
44. D. Singh A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients Pulm. Pharmacol. Ther. 25 3 2012 248 253
45. P. Chanez Aclidinium bromide provides long-acting bronchodilation in patients with COPD Pulm. Pharmacol. Ther. 23 1 2010 15 21
46. P.W. Jones Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease Respir. Res. 12 2011 55
47. F. Maltais Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD Respir. Med. 105 4 2011 580 587
48. E.M. Kerwin Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I) COPD 9 2 2012 90 101
49. P.W. Jones Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study Eur. Respir. J. 40 4 2012 830 836
50. M. Salmon Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases J. Pharmacol. Exp. Ther. 345 2 2013 260 270
51. A. Cahn Safety, tolerability, pharmocodynamics (PD0 and pharmocokinetics (PK) of GSK573719 inhalation powder in healthy subjects ERJ 38 Suppl 55, 723s 2011 A3971
52. R. Mehta Safety, tolerability and pharcokinetics (PK) of repeated doses of GSK573719 inhalation powder, a noew long-acting muscarinic antagonist, in healthy adults Eur. Respir. J. 38 Suppl 55, 723s 2011 A3972
53. D. Kelleher Absorption, distribution, metabolism, and elimination (ADME) of umeclidinium (UMEC) in healthy adults Eur. Respir. J. 40 Suppl 56, 384s 2012 A2153
54. R. Mehta Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD Eur. Respir. J. 38 Suppl 55, 138s 2011 A822
55. R. Mehta Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study Int. J. Chron. Obstruct. Pulmon. Dis. 8 2013 159 167
56. M. Decramer Dose related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD Eur. Respir. J. 38 Suppl 55, 150s 2011 A878
57. J.F. Donohue A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD Respir. Med. 106 7 2012 970 979
58. J. Beier Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients Int. J. Chron. Obstruct. Pulmon. Dis. 7 2012 153 164
59. E. Bateman Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD Clin. Respir. J. 6 4 2012 248 257
60. M. Cazzola Long-acting muscarinic receptor antagonists for the treatment of respiratory disease Pulm. Pharmacol. Ther. 26 3 2013 307 317
61. T. Steinfield In vitro, characterisation of TD-4208, a lung-selective and long-acting muscarinic antagonist bronchodilator Am. J. Respir. Cell Mol. Biol. 179 2009 A4553
62. M.T. Pulido-Rios In vivo pharmacological characterization of TD-4208, a novel lung selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models J. Pharmacol. Exp. Ther. 2013
63. P. Potgieter A randomised, crossover study to examine the pharmacodynamics and safety of a new antimuscarinic (TD-4208) in COPD Eur. Respir. J. 40 Suppl 56, 524s 2012 A2878
64. Theravance initiates TD-4208 phase 2b dose ranging study Pharm. Bus. Rev. 2012, December
65. L. Bjermer Local and systemic effects of inhaled AZD9164 compared with tiotropium in patients with COPD Respir. Med. 107 1 2013 84 90
66. A. Mete The discovery of AZD9164, a novel muscarinic M3 antagonist Bioorg. Med. Chem. Lett. 21 24 2011 7440 7446
67. A double-blind, double-dummy, placebo-controlled, randomised, multi-centre, 5-way cross-over, single-dose study to investigate the local and sytemic effects of inhaled AZD9164 compared to tiotropium in subjects with Chronic Obstructive Pulmonary disease (COPD), Clinical Study Report Synopsis of AZD9164 AztraZeneca 2010
68. S. Gupta Pharmacodynamic and pharmacokinetic profile of RBx 343E48F0: a novel, long acting muscarinic receptor antagonist Eur. J. Pharmacol. 658 2-3 2011 219 228
69. 3 antagonist Eur. Respir. J. 36 Suppl 54, 219s 2010 A1237
70. L. Oleson ALKS 27 (Trospium inhalation powder) improves lung function following single administration in subjects with COPD Am. J. Respir. Crit. Care Med. 181 2010 A4457
71. N. Hertel Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis Int. J. Chron. Obstruct. Pulmon. Dis. 7 2012 183 199
72. R. Kodgule Newer therapies for chronic obstructive pulmonary disease J. Assoc. Phys. India 60 Suppl 2012 8 13
73. P. Norman Dual-acting beta2 agonists/muscarinic antagonists Expert Opin. Ther. Pat. 16 9 2006 1327 1331